EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
12.80
-0.49 (-3.69%)
At close: Feb 3, 2026, 4:00 PM EST
12.99
+0.19 (1.48%)
After-hours: Feb 3, 2026, 7:21 PM EST
EyePoint Revenue
EyePoint had revenue of $966.00K in the quarter ending September 30, 2025, a decrease of -90.82%. This brings the company's revenue in the last twelve months to $42.34M, down -7.38% year-over-year. In the year 2024, EyePoint had annual revenue of $43.27M, down -5.97%.
Revenue (ttm)
$42.34M
Revenue Growth
-7.38%
P/S Ratio
21.54
Revenue / Employee
$256,600
Employees
165
Market Cap
1.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
| Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
| Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
| Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
| Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
| Dec 31, 2019 | 20.37M | 15.79M | 345.53% |
| Dec 31, 2018 | 4.57M | 1.61M | 54.37% |
| Sep 30, 2018 | 2.96M | - | - |
| Jun 30, 2018 | 2.96M | - | - |
| Dec 31, 2017 | 2.96M | -4.58M | -60.72% |
| Jun 30, 2017 | 7.54M | - | - |
| Dec 31, 2016 | 7.54M | 5.92M | 365.37% |
| Jun 30, 2016 | 1.62M | - | - |
| Dec 31, 2015 | 1.62M | -24.95M | -93.90% |
| Jun 30, 2015 | 26.57M | 23.09M | 664.90% |
| Jun 30, 2014 | 3.47M | 1.33M | 62.06% |
| Jun 30, 2013 | 2.14M | -1.38M | -39.22% |
| Jun 30, 2012 | 3.53M | -1.44M | -28.98% |
| Jun 30, 2011 | 4.97M | -18.09M | -78.46% |
| Jun 30, 2010 | 23.05M | 10.89M | 89.55% |
| Jun 30, 2009 | 12.16M | 8.69M | 249.88% |
| Jun 30, 2008 | 3.48M | 1.69M | 94.73% |
| Jun 30, 2007 | 1.79M | 749.00K | 72.30% |
| Jun 30, 2006 | 1.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 147.19M |
| Day One Biopharmaceuticals | 133.67M |
| AbCellera Biologics | 35.33M |
| Septerna | 22.05M |
| Inventiva | 19.93M |
| Capricor Therapeutics | 11.13M |
| Aktis Oncology | 5.56M |
| Inhibrx Biosciences | 1.40M |
EYPT News
- 18 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 27 days ago - EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 - GlobeNewsWire
- 6 weeks ago - EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration - GlobeNewsWire
- 3 months ago - EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 3 months ago - EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewsWire